company background image
MNKK.Q logo

Mallinckrodt OTCPK:MNKK.Q Stock Report

Last Price

US$0.02

Market Cap

US$1.7m

7D

-67.2%

1Y

-96.0%

Updated

19 Jun, 2022

Data

Company Financials

This company listing is no longer active

This company may still be operating, however this listing is no longer active. Find out why through their latest events.

MNKK.Q Stock Overview

Mallinckrodt plc develops, manufactures, markets, and distributes specialty pharmaceutical products and therapies in the United States, Europe, the Middle East, Africa, and internationally.

MNKK.Q fundamental analysis
Snowflake Score
Valuation3/6
Future Growth0/6
Past Performance0/6
Financial Health4/6
Dividends0/6

Mallinckrodt plc Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Mallinckrodt
Historical stock prices
Current Share PriceUS$0.02
52 Week HighUS$0.59
52 Week LowUS$0.001
Beta2.72
1 Month Change-79.38%
3 Month Change-83.33%
1 Year Change-95.95%
3 Year Change-99.78%
5 Year Change-99.96%
Change since IPO-99.96%

Recent News & Updates

Recent updates

Shareholder Returns

MNKK.QUS PharmaceuticalsUS Market
7D-67.2%-0.2%0.6%
1Y-96.0%23.9%29.5%

Return vs Industry: MNKK.Q underperformed the US Pharmaceuticals industry which returned 7% over the past year.

Return vs Market: MNKK.Q underperformed the US Market which returned -20.6% over the past year.

Price Volatility

Is MNKK.Q's price volatile compared to industry and market?
MNKK.Q volatility
MNKK.Q Average Weekly Movement27.3%
Pharmaceuticals Industry Average Movement9.5%
Market Average Movement6.0%
10% most volatile stocks in US Market16.9%
10% least volatile stocks in US Market3.0%

Stable Share Price: MNKK.Q's share price has been volatile over the past 3 months.

Volatility Over Time: MNKK.Q's weekly volatility has increased from 21% to 27% over the past year.

About the Company

FoundedEmployeesCEOWebsite
18672,789Mark Trudeauhttps://www.mallinckrodt.com

Mallinckrodt plc develops, manufactures, markets, and distributes specialty pharmaceutical products and therapies in the United States, Europe, the Middle East, Africa, and internationally. It operates in two segments, Specialty Brands and Specialty Generics. The company markets branded pharmaceutical products for autoimmune and rare diseases in the areas of neurology, rheumatology, nephrology, ophthalmology, pulmonology, and oncology; immunotherapy and neonatal respiratory critical care therapies; analgesics; cultured skin substitutes; and gastrointestinal products.

Mallinckrodt plc Fundamentals Summary

How do Mallinckrodt's earnings and revenue compare to its market cap?
MNKK.Q fundamental statistics
Market capUS$1.70m
Earnings (TTM)-US$699.50m
Revenue (TTM)US$2.14b

0.7x

P/S Ratio

-2.2x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
MNKK.Q income statement (TTM)
RevenueUS$2.14b
Cost of RevenueUS$1.32b
Gross ProfitUS$817.00m
Other ExpensesUS$1.52b
Earnings-US$699.50m

Last Reported Earnings

Apr 01, 2022

Next Earnings Date

n/a

Earnings per share (EPS)-8.25
Gross Margin38.15%
Net Profit Margin-32.66%
Debt/Equity Ratio712.6%

How did MNKK.Q perform over the long term?

See historical performance and comparison
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.